Statistical analysis
NSCLC
NSCLC
Referring to previous studies and data for similar agents, the median PFS of icotinib in the first-line treatment of EGFR-positive NSCLC was estimated at 9.9 months [The full analysis set (FAS), based on the intention-to-treat (ITT) population, included all participants who used the study drugs at least once. EAS(efficacy analysis set)was used for efficacy analysis, which at least first response evaluation. The safety set (SS) included all participants who used the study drugs at least once with available safety assessments after using the study drugs. SS was used for safety analysis.Statistical analysis was performed using SAS 9.1.3 (SAS Institute, Cary, NC, USA). Continuous data were presented as mean ± standard deviation if normally distributed or median (minimum, maximum) if skewedly distributed. Categorical data were described as n (%), and 95% confidence intervals (CIs) were determined. The Kaplan-Meier method was utilized to display PFS and OS, and safety analysis was mostly descriptive statistical analysis. Survival curves were compared by the log-rank test. P < 0.05 indicated statistical significance.